RNA Insights – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

RNA Insights

Eclipsebio

Forme & Santé

Fréquence : 1 épisode/29j. Total Éps: 6

From mRNA vaccines to RNA-editing therapies, RNA and RNA-based therapeutics are the future of health and medicine — and new insights are made every day. In each episode of RNA Insights by Eclipsebio, host Grace Gudwien chats with a different RNA expert about their career and how their work has impacted RNA therapeutics and RNA research. We also review the latest RNA industry news and look forward to what's next in the world of RNA medicine.

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 26/09/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10294746/
2 partages
https://pmc.ncbi.nlm.nih.gov/articles/PMC3118090/
2 partages
https://pmc.ncbi.nlm.nih.gov/articles/PMC12719227/
2 partages

https://pubmed.ncbi.nlm.nih.gov/19701183/
2 partages
https://pubmed.ncbi.nlm.nih.gov/25768907/
2 partages
https://pubmed.ncbi.nlm.nih.gov/22072978/
2 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 58%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Episode 6: Uniting the science, business, and strategy of mRNA therapeutics with Deborah Day Barbara

Saison 1 · Épisode 6

mercredi 23 septembre 2026 • Durée 31:12

On this episode of RNA Insights, we talk with Deborah Day Barbara about her experience in academia, industry, and business strategy, as well as her thoughts on the rapidly growing RNA therapeutics industry.

Resources referenced in the episode:

Kary Mullis’s Nobel Prize: https://www.nobelprize.org/prizes/chemistry/1993/mullis/facts/
Johns Hopkins Technology Ventures: https://ventures.jhu.edu/
Gene Logic: http://www.genelogic.com
Strategic Diagnostics (now SDIX): https://www.sdix.com/
Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy: https://pmc.ncbi.nlm.nih.gov/articles/PMC10294746/
mRNA: The Fourth Pillar of Pharmaceutical Innovation and Intervention: https://www.advancingrna.com/doc/mrna-the-fourth-pillar-of-pharmaceutical-innovation-and-intervention-0001
Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies – challenges and opportunities: https://www.sciencedirect.com/science/article/abs/pii/S0168365924002438
Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review: https://pubs.acs.org/mpohbp/article-abstract/22/8/4474/3750518/Recent-Advances-in-mRNA-LNP-Delivery-Systems-for
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients: https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/
Valerio Therapeutics announces signing of definitive agreements for the acquisition of Etherna Immunotherapies, building a leading platform in targeted RNA, and €40.25 million PIPE financing from new and existing investors: https://valeriotx.com/valerio-therapeutics-announces-signing-of-definitive-agreements-for-the-acquisition-of-etherna-immunotherapies-building-a-leading-platform-in-targeted-rna-and-e40-25-million-pipe-financing-from-new-2/

Music by Ievgen Poltavskyi from Pixabay

Sound Effect by Ribhav Agrawal from Pixabay

Eclipsebio host: Grace Finnell-Gudwien

Lire plusRéduire

Episode 5: Uncovering the longevity of mRNA with Dr. Jeff Coller

Saison 1 · Épisode 5

vendredi 28 août 2026 • Durée 52:24

On this episode of RNA Insights, we talk with Dr. Jeff Coller about discovering how codons relate to mRNA stability, how codon optimality can help treat genetic diseases, and why science communication is essential to the field of RNA medicine.

Resources referenced in the episode:

Sjöberg’s research group’s website: https://www.su.se/english/research/research-catalogue/research-groups/4/britt-marie-sjobergs-research-group
Wickens’s laboratory website: https://wickenslab.biochem.wisc.edu/
Coller’s laboratory website: http://www.collerlab.org/
Co-translational mRNA decay in Saccharomyces cerevisiae: https://pubmed.ncbi.nlm.nih.gov/19701183/
Codon optimality is a major determinant of mRNA stability: https://pubmed.ncbi.nlm.nih.gov/25768907/
More information on Gaucher Disease: https://www.gaucherdisease.org/about-gaucher-disease/what-is/
More information on Dravet Syndrome: https://dravetfoundation.org/what-is-dravet-syndrome/
Coller’s LinkedIn: https://www.linkedin.com/in/jeffcoller/
AMM ASCENT: https://mrnamedicines.org/events/2026-annual-meeting/
4BaseBio: https://www.4basebio.com/

Episode 4: How RNA therapeutics can change the world of rare diseases with Dr. Tamar Grossman

Saison 1 · Épisode 4

vendredi 24 juillet 2026 • Durée 36:00

On this episode of RNA Insights, we chat with Dr. Tamar Grossman about her years of experience with ASOs and rare diseases, how she navigates multiple roles at once, and how new technologies are expediting the process of developing individualized RNA-based treatments.

Resources referenced in the episode:

Over-expression of DSCAM and COL6A2 cooperatively generates congenital heart defects: https://pubmed.ncbi.nlm.nih.gov/22072978/
Grossman’s publications: https://www.researchgate.net/profile/Tamar-Grossman-3
Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide: http://www.molvis.org/molvis/v23/561/
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen: https://www.sciencedirect.com/science/article/pii/S0171298525000105?via%3Dihub
Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease: https://academic.oup.com/brain/article/144/10/2985/6276430
La Jolla Lab’s website: https://www.lajollalabs.ai/
La Jolla Lab's email: info@lajollalabs.net
The n-of-1 clinical trial: The ultimate strategy for individualizing medicine?: https://pmc.ncbi.nlm.nih.gov/articles/PMC3118090/
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS: https://www.biospace.com/press-releases/la-jolla-labs-inc-announces-first-patient-treated-with-custom-antisense-therapy-gbfsen-for-familial-als

Episode 3: Exploring nonsense-mediated decay and celebrating the RNA research community with Dr. Kristian Baker

Saison 1 · Épisode 3

lundi 29 juin 2026 • Durée 35:24

On this episode of RNA Insights, we chat with Dr. Kristian Baker about the relationship between nonsense-mediated decay and mRNA therapeutics as well as Baker's dual roles in research and science advocacy.

Resources referenced in the episode:

Ectopic RNase E sites promote bypass of 5'-end-dependent mRNA decay in Escherichia coli: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2958.2003.03292.x
In vivo-compatible proximity labeling technologies: https://www.sciencedirect.com/science/article/abs/pii/S1367593126000165
Analysis of Nonsense-Mediated mRNA Decay in Saccharomyces cerevisiae: https://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471143030.cb2703s54
Single-Gene Disorders: https://www.ncbi.nlm.nih.gov/books/NBK132154/
Prime editing-installed suppressor tRNAs for disease-agnostic genome editing https://www.nature.com/articles/s41586-025-09732-2
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome: https://www.cell.com/immunity/fulltext/S1074-7613(26)00075-0
RNA Society Journal: https://www.rnasociety.org/about-the-society/journal/
RNA Society website: https://www.rnasociety.org/
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine:

Episode 2: RNA helicases and the rise of mRNA therapeutics with Dr. Eckhard Jankowsky

Saison 1 · Épisode 2

jeudi 28 mai 2026 • Durée 35:08

On this episode of RNA Insights, we chat with Dr. Eckhard Jankowsky about his work with RNA helicases and their impact on health, his transition from academia to Big Pharma, and how the past three decades of RNA therapeutic research will influence the future of RNA medicine.

Resources referenced in the episode:

The DEAH-box protein PRP22 is an ATPase that mediates ATP-dependent mRNA release from the spliceosome and unwinds RNA duplexes: https://pubmed.ncbi.nlm.nih.gov/9582286/

The DExH protein NPH-II is a processive and directional motor for unwinding RNA: https://pubmed.ncbi.nlm.nih.gov/10667799/

Jankowsky’s publications: https://scholar.google.com/citations?hl=en&user=z6F2cuoAAAAJ

More information on DDX3X: https://www.ncbi.nlm.nih.gov/gene/1654

More information on DDX3X syndrome: https://www.ucsf.edu/news/2020/03/416816/scientists-unravel-mystery-rare-genetic-disorder-causes-intellectual-disability

The Viral Protein K7 Inhibits Biochemical Activities and Condensate Formation by the DEAD-box Helicase DDX3X: https://www.sciencedirect.com/science/article/abs/pii/S0022283623003169

Hidden specificity in an apparently non-specific RNA-binding protein: https://pmc.ncbi.nlm.nih.gov/articles/PMC3800043/#S1

How eCLIP revolutionized RNA-based therapeutic research with Dr. Gene Yeo   

Saison 1 · Épisode 1

jeudi 30 avril 2026 • Durée 36:40

Welcome to RNA Insights, an RNA therapeutics podcast hosted by Eclipsebio. Each month, we interview a different expert in the field of RNA and RNA-based medicine about their career and thoughts on the ever-evolving RNA therapeutic space.

On this inaugural episode, we talk with Dr. Gene Yeo, co-developer of the eCLIP protocol and co-founder of Eclipsebio, about his journey identifying the need for and developing a more efficient method of crosslinking immunoprecipitation that changed the ways scientists perform RNA research.

Resources referenced in the episode:

Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals: https://pubmed.ncbi.nlm.nih.gov/15285897/

Identification and analysis of alternative splicing events conserved in human and mouse: https://pubmed.ncbi.nlm.nih.gov/15708978/

Yeo Lab Publications: https://yeolab.com/publications

ENCODE Overview: https://www.encodeproject.org/help/project-overview/

Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP): https://www.nature.com/articles/nmeth.3810

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics: https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à RNA Insights. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !